Table 2. Uinvariate and multivariate analysis of factors associated with survival time of patients with prostate cancer.
| Clinical variable | Case number | HR(95% CI) | p Value |
|---|---|---|---|
| Uinvariate analysis | |||
| MiR-23a (low vs high) | 62/61 | 0.389 (0.249–0.608) | 0.000 |
| Age (> 68.5 vs 68.5) | 57/66 | 0.976 (0.635–1.501) | 0.913 |
| PSA level (> 10 vs ≤ 10) | 50/64 | 1.782 (1.159–2.741) | 0.009 |
| Gleason (> 7 vs ≤ 7) | 32/91 | 4.941 (3.096–7.885) | 0.000 |
| Distant metastasis (M1 vs M0) | 12/111 | 15.724 (7.829–31.580) | 0.000 |
| Pathologic stage (> T2 vs T1) | 33/90 | 2.242 (1.428–3.520) | 0.000 |
| multivariate analysis | |||
| miR-23a (low vs high) | 62/61 | 1.776 (1.116–2.829) | 0.015 |
| Pathologic stage (> T2 vs T1) | 33/90 | 1.724 (1.009–2.946) | 0.046 |
| Gleason (> 7 vs ≤ 7) | 32/91 | 4.026 (2.415–6.712) | 0.000 |
| Distant metastasis (M1 vs M0) | 33/90 | 7.908 (3.529–17.719) | 0.000 |